Vanadium(IV) oxide affects embryonic development in mice

Oxidative damage and cell cycle delay induced by vanadium(III) in human peripheral blood cells

Vanadium (V) is a metal that can enter the environment through natural routes or anthropogenic activity. In the atmosphere, V is present as V oxides, among which vanadium(III) oxide (V2O3) stands out. Cytogenetic studies have shown that V2O3 is genotoxic and cytostatic and induces DNA damage; however, the molecular mechanisms leading to these effects have not been fully explored. Therefore, we treated human peripheral blood lymphocytes in vitro, evaluated the effects of V2O3 on the phases of the cell cycle and the expression of molecules that control the cell cycle and examined DNA damage and the induction of oxidative stress. The results revealed that V2O3 did not affect cell viability at the different concentrations (2, 4, 8 or 16 μg/mL) or exposure times (24 h) used. However, V2O3 affected the percentage of G1- and S-phase cells in the cell cycle, decreased the expression of mRNAs encoding related proteins (cyclin D, cyclin E, CDK2 and CDK4) and increased the expression of γH2AX and the levels of reactive oxygen species. The ability of V2O3 to cause a cell cycle delay in G1-S phase may be associated with a decrease in the mRNA and protein expression of the cyclins/CDKs and with intracellular oxidative stress, which may cause DNA double-strand damage and H2AX phosphorylation.

Prenatal metal exposures and kidney function in adolescence in Project Viva

BACKGROUND

The developing kidney is vulnerable to prenatal environmental factors such as metal exposure, potentially altering the risk of later-life kidney dysfunction. This study examines the relationship between prenatal metal exposures, individually and as mixtures, and adolescent kidney function in Project Viva, a prospective longitudinal birth cohort in Massachusetts, USA.

METHODS

We used data on metals measured in blood during pregnancy including 15 in the first trimester and four in the second trimester. We calculated estimated glomerular filtration rate (eGFR) in adolescents (mean: 17.7 years) using cystatin C- (eGFRcys) and creatinine-based (eGFRcreat) equations for children. We used linear regression for single metal analyses, and Bayesian kernel machine regression and quantile-based g-computation for mixture analyses, adjusting for relevant covariates. To account for multiple comparisons in the single metal analyses, we applied the Holm-Bonferroni procedure to control the false discovery rate.

RESULTS

This study included 371 participants with first trimester metals and adolescent eGFR, and 256 with second trimester metals. Each doubling in first trimester cadmium concentration was associated with lower adolescent eGFRcys (β:-1.51; 95% CI:-2.83, -0.18). Each doubling in first trimester chromium (β:-1.45; 95% CI:-2.71, -0.19), nickel (β:-1.91; 95% CI:-3.65, -0.16), and vanadium (β:-1.69; 95% CI:-3.21, -0.17) was associated with lower adolescent eGFRcreat. After adjusting for multiple comparisons, p-values for associations between adolescent eGFR and chromium, nickel, vanadium and cadmium did not meet the criteria for significance. Metal mixture analyses did not identify statistically significant associations with adolescent eGFR.

CONCLUSIONS

These findings have important implications for future studies investigating the potential mechanisms through which prenatal metal exposures affect long-term kidney health in children.

Biodistribution of Vanadium Dioxide Particles in Mice by Consecutive Gavage Administration: Effects of Particle Size, Dosage, and Health Condition of Mice

The newly developed vanadium dioxide (VO₂), a material with excellent reversible and multi-stimuli responsible phase transition property, has been widely used in high-performance and energy-saving smart devices. The rapid growth of the VO₂-based emerging technologies and the complex biological effect of vanadium to organisms urge a better understanding of the behavior of VO₂ in vivo for safety purpose. Herein, we study the absorption, distribution, and excretion of two commercial VO₂ (nanoscale SVO₂ and bulk MVO₂) in mice after consecutive gavage administration for up to 28 days. The absorption of both types of VO₂ is as low as less than 1.5% of the injected dose within 28 days, while MVO₂ is several times more difficult to be absorbed than SVO₂. Almost all unabsorbed VO₂ is excreted through feces. For the absorbed vanadium, bone is the organ with the largest accumulation, followed by liver, kidney, and spleen. The vanadium content in organs shows a size-, dosage-, and animal health condition-dependent manner, and increases gradually to a saturation value along with the consecutive administration. Generally, smaller particle size and higher dosage lead to higher vanadium contents in organs, and more vanadium accumulates in bone and liver in diabetic mice than in normal mice. After the treatment is stopped, the accumulated vanadium in organs decreases a lot within 14 days, even reaches to the background level in some organs, but the content of vanadium in the bone remains high after 14 days post-exposure. These findings provide basic information for the safety assessment and safe applications of VO₂-based materials.